CION Ameerpet
“Gynae cancer” is not one disease. Ovarian, cervical and endometrial cancer start in three different organs, have three different causes, and are found in three different ways. Knowing which one you are reading about changes almost everything that follows.
Doctors group ovarian, cervical and endometrial cancer together as “gynae cancers” because they all arise in the female reproductive tract. That grouping is administrative, not biological. If you have typed difference ovarian cervical endometrial cancer into a search box, the honest answer is that these three have far less in common than their shared label suggests.
The organ each one starts in decides its cause, the age it usually appears, the first symptom it produces, whether it can be found before it causes symptoms at all, and how it is treated. Cervical cancer is driven by a virus and can largely be prevented. Endometrial cancer is driven by hormones and usually announces itself early, with bleeding. Ovarian cancer has no single cause, no screening test, and symptoms so vague they are routinely put down to indigestion.
This page sets the three side by side. If you already know which one concerns you, the ovarian cancer guide, the cervical cancer guide and the endometrial (uterine) cancer guide each go considerably deeper than anything here.
Where ovarian cancer starts. Most high-grade serous cancers are now thought to begin in the fallopian tube and spread to the ovary and the abdominal lining. The ovaries sit deep in the pelvis with room to grow quietly, which is why the symptoms arrive late and vaguely.
The neck of the womb, visible at the top of the vagina. Because it can be seen, swabbed and sampled in a two-minute examination, it is the one gynaecological cancer with a screening programme that genuinely works.
The lining of the womb, shed as a period each month. Cancer here disturbs that lining and causes bleeding early, which is why most endometrial cancer is caught while it is still confined to the uterus.
One table, nine differences. Read down the column that matches your concern rather than across all three.
| Feature | Ovarian cancer | Cervical cancer | Endometrial (uterine) cancer |
|---|---|---|---|
| Where it starts | The ovary or fallopian tube. Most high-grade cancers are now thought to begin in the tube. | The cervix, the neck of the womb, which opens into the vagina. | The endometrium, the lining of the womb itself. |
| Main cause | No single cause. Inherited BRCA and Lynch variants and a lifetime of ovulation carry much of the risk. | Persistent infection with a high-risk HPV type, in virtually every case. | Long-term oestrogen exposure unopposed by progesterone. Obesity is the largest modifiable driver. |
| Typical age | Most often after the menopause. Rarer germ-cell types occur in young women. | Often younger than the other two, which is why it takes so many working-age lives. | Mostly after the menopause. |
| Usual first symptom | Vague and abdominal: bloating, feeling full quickly, pelvic pain, urinary urgency. | Bleeding after sex, between periods or after the menopause; watery or blood-stained discharge. | Bleeding after the menopause — the commonest presentation, and an early one. |
| Can it be screened for? | No. No screening test has been shown to save lives, including in BRCA carriers. | Yes. HPV testing and cytology find pre-cancer years before cancer develops. | No screening test. Postmenopausal bleeding acts as the early alarm instead. |
| Can it be prevented? | Partly. Risk-reducing surgery for confirmed high-risk carriers; no vaccine exists. | Largely. HPV vaccination plus screening prevents most cases. | Partly. Weight, blood-sugar control and progestogen-containing regimens reduce risk. |
| Usual stage at diagnosis | Most often advanced, because the symptoms are vague and there is no screening. | Varies widely. Screen-detected disease is early; unscreened women often present late. | Usually early, because bleeding brings women in quickly. |
| How it is confirmed | Imaging and tumour markers, then tissue — frequently obtained at surgery. | Colposcopy with a cervical biopsy, usually as an outpatient. | Endometrial biopsy or hysteroscopy after an ultrasound measures the lining. |
| Backbone of treatment | Surgery to remove all visible disease, plus platinum-based chemotherapy and maintenance therapy. | Early disease: surgery. Locally advanced disease: chemoradiation rather than an operation. | Surgery — hysterectomy with surgical staging — often on its own in early disease. |
*A general pattern, not a rule for any individual. Age ranges overlap, and every one of these cancers occurs outside its typical picture.
Of these three cancers, only one can be screened for. In 2020 the World Health Assembly adopted the WHO global strategy to eliminate cervical cancer as a public health problem, built on three targets to be met by 2030: 90% of girls fully vaccinated against HPV by age 15, 70% of women screened with a high-performance test by age 35 and again by 45, and 90% of women with cervical disease treated. No comparable strategy exists for ovarian or endometrial cancer — not because they matter less, but because neither has a screening test shown to save lives in the general population. Source: WHO, Global Strategy to Accelerate the Elimination of Cervical Cancer as a Public Health Problem (2020); NCCN and FIGO guidance on ovarian and endometrial cancer.
Cause, symptoms, screening, diagnosis, staging, treatment and inherited risk. On every one of these, the three separate.
Cervical cancer is, in virtually every case, the long-term consequence of persistent infection with a high-risk type of human papillomavirus. HPV is extremely common and is almost always cleared by the immune system within about two years. In a minority of women it persists, and over ten to twenty years it can push normal cervical cells through pre-cancerous change into cancer. That long, visible runway is exactly what makes screening work.
Endometrial cancer is largely hormonal. Oestrogen stimulates the womb lining and progesterone opposes it. Anything that tips that balance towards prolonged unopposed oestrogen raises the risk: obesity, polycystic ovary syndrome, few or no pregnancies, late menopause, oestrogen-only hormone replacement, and long-term hormonal treatment for breast cancer. Obesity is the single largest modifiable driver.
Ovarian cancer has no single cause. Inherited variants in BRCA1, BRCA2 and the Lynch syndrome genes account for a meaningful minority of cases, and a lifetime of uninterrupted ovulation appears to add risk, which is why pregnancy and combined oral contraception are both protective. For most women, no cause is ever identified.
Bleeding is a loud symptom. The cervix and the endometrium both bleed when they are disturbed, so cervical and endometrial cancer tend to declare themselves with bleeding after sex, between periods, or after the menopause. That is frightening to experience but clinically useful: it brings women to a doctor while the disease is still small.
The ovary has no such alarm. It sits deep in the pelvis with room to expand, and what it eventually produces is pressure rather than bleeding: bloating, feeling full quickly, pelvic pain and urinary urgency. Every one of those is far more commonly caused by irritable bowel syndrome, constipation or ordinary indigestion, which is precisely why ovarian cancer is so often diagnosed late. The pattern that earns a check is a new, persistent one, present on more than 12 days in a month.
Cervical screening — HPV testing, cytology, or both — finds pre-cancerous change years before a cancer develops, and treating that change prevents the cancer altogether. It is one of the most successful cancer-prevention programmes in medicine, and HPV vaccination adds to it by preventing the infection in the first place.
There is no screening test for ovarian cancer. Large randomised trials of CA-125 blood testing and ultrasound in healthy women did not show that screening saves lives, and both tests produce false alarms that lead to operations on benign cysts. This holds for BRCA carriers too: surveillance does not protect, which is why risk-reducing surgery rather than scanning is what is offered to women at high inherited risk.
There is no screening test for endometrial cancer either. What substitutes for one is the symptom: any bleeding after the menopause should be investigated, and investigating it promptly catches most endometrial cancers at an early stage, when surgery alone is often enough.
Suspected cervical cancer is assessed by looking at the cervix. A speculum examination, then colposcopy — the cervix magnified and stained — and a biopsy of anything abnormal. It is an outpatient sequence and usually gives a tissue answer within days.
Suspected endometrial cancer starts with a transvaginal ultrasound to measure the thickness of the womb lining, followed by an endometrial biopsy or a hysteroscopy to sample it directly. Again, a tissue answer is normally available quickly.
Suspected ovarian cancer is the awkward one. Where an early, potentially operable cancer is suspected, the ovary is not biopsied through the abdominal wall, because puncturing it risks spilling cells into the abdomen. The work-up is therefore indirect: ultrasound, CA-125 and often HE4 or a ROMA score, then CT imaging, with the definitive diagnosis frequently made on tissue removed at surgery.
All three are staged with the FIGO system, running from stage I, confined to the organ of origin, to stage IV, spread to distant sites. The stage numbers are not comparable across the three, because the same number describes a different anatomical situation in each.
Ovarian and endometrial cancer are staged surgically: the true stage is known only after the abdomen has been examined and tissue sampled. Cervical cancer was historically staged clinically, by examination alone, because it is common in settings without ready access to imaging or surgery; the FIGO 2018 revision allows imaging and pathology findings to be used where they are available.
This matters when you read survival figures. A stage III ovarian cancer and a stage III cervical cancer are different diseases, assessed by different methods and treated in different ways. Setting the two percentages beside each other tells you very little.
Ovarian cancer is treated with surgery to remove all visible disease combined with platinum-based chemotherapy, given before surgery, after it, or both. Many women then continue on maintenance therapy of the PARP-inhibitor or anti-angiogenic class to delay recurrence, and BRCA and HRD testing guides that choice. There is more detail on ovarian cancer treatment in Hyderabad.
Cervical cancer splits by stage. Early disease is treated surgically, sometimes with fertility-sparing surgery in young women who have not completed their families. Locally advanced disease is treated with chemoradiation — radiotherapy given alongside chemotherapy that sensitises the tumour to it — rather than with an operation.
Endometrial cancer is treated primarily with surgery: removal of the uterus, tubes and ovaries with surgical staging. In early, low-risk disease that is often the whole treatment. Radiotherapy, chemotherapy or hormonal treatment is added according to grade, depth of invasion into the muscle wall and, increasingly, the molecular subgroup the tumour falls into.
The clearest overlap between these cancers is inherited risk. BRCA1 and BRCA2 variants raise ovarian and breast cancer risk substantially and do not raise cervical or endometrial risk. Lynch syndrome raises the risk of bowel, endometrial and ovarian cancer together, and in women it is frequently endometrial cancer that appears first.
Cervical cancer is the outlier. Its cause is an infection rather than an inherited gene, so it does not cluster in families for genetic reasons, although a family pattern may reflect shared screening habits that are worth correcting.
If ovarian, breast, bowel or endometrial cancer runs in your family, genetic counselling is the right next step rather than more scans. CION provides genetic counselling and BRCA and HRD testing in-house, including cascade testing for relatives once a variant has been found in the family.
None of these means cancer, and most people who have them do not have it. Each one has a specific first test attached to it, which is the practical reason to know which is which.
Points first at the endometrium. Most cases turn out to be a thinned lining or a benign polyp, but this is how the majority of endometrial cancers present, and it always needs an ultrasound, usually with a biopsy.
Points first at the cervix. It needs a speculum examination whatever your last screening result said — screening lowers risk, it does not remove the need to look. See cervical cancer.
Points at the ovary, particularly when it is new and does not settle. This pattern, not bloating on its own, is what research has repeatedly found meaningful.
An ovarian pattern, especially alongside bloating. Two of these symptoms together carry more weight than either alone.
Non-specific: it occurs in all three, and far more often in none of them. New pelvic pain that persists in a woman past the menopause warrants an examination and a scan.
Occurs in both cervical and endometrial cancer and is easy to dismiss as an infection. Discharge that continues after an infection has been treated needs a look at the cervix.
If any of these apply, the useful next step is one appointment, not more searching. In the great majority of cases the assessment ends in reassurance — and in the minority where it does not, all three of these cancers are far more treatable when they are found early.
One 45-minute consultation, one examination and usually one scan will separate them. Most women leave with a benign explanation and a clear next step rather than a longer list of tests.
We're never more than 30 minutes away. Same panel of specialists at every centre. Same tumour board reviews. Same NCCN protocols. Pick the closest one and call directly — or let us pick for you.
CION Ameerpet
CION Kukatpally
CION L.B. Nagar
CION Tolichowki
CION Masab Tank
CION Banjara Hills
CION Kompally
CION Balanagar
CION Siddipet
CION Sangareddy
Not sure which centre fits best? Tell us where you are — we'll suggest the closest one with the right specialists.
Help me pick the right centreTravelling for treatment? We may have a centre right where you are.
Don't see your city? Call 18002028726 — we'll find your nearest CION partner centre.
Trained at AIIMS, Tata Memorial and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them - together.
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationShare your name and number — we'll call you back within 30 minutes to schedule your consultation.
No referral needed and no cost for the first consultation. If the answer is that nothing is wrong, we will tell you plainly and send you home.
There is no single test that separates them. The sequence below does, and most women reach a clear answer within the first three steps.
What the symptom actually is, how long it has been there, whether it is bleeding or pressure, whether you are before or after the menopause, and what runs in your family. Bleeding steers the assessment towards the cervix and the endometrium; bloating and early fullness steer it towards the ovary. CION consultations run to 45 minutes precisely so this part is not rushed.
An abdominal examination looks for distension, a palpable mass and free fluid. A speculum examination lets the cervix be seen directly and swabbed. A bimanual examination assesses the size and mobility of the uterus and ovaries. This ten-minute sequence often decides which of the three is in question.
One scan answers questions about all three organs. It characterises the ovaries, measures the thickness of the endometrium, and identifies fibroids, cysts and free fluid. It is painless and radiation-free, and in most women it finds a benign explanation rather than merely excluding a frightening one.
Cervix: colposcopy, with a biopsy of anything abnormal. Endometrium: an endometrial biopsy or hysteroscopy. Ovary: CA-125, often with HE4 and a ROMA score, interpreted alongside the scan and your menopausal status rather than read on its own.
A diagnosis is made on tissue, not on a scan or a blood test. Once it is made, cross-sectional imaging defines the extent of disease and the case goes to a tumour board — medical oncology, radiation oncology, imaging and pathology together — before any treatment starts.
*Not every step is needed. A woman with cyclical bloating, a normal examination and a normal scan does not need a CA-125, and ordering one anyway tends to create anxiety rather than answers.
Most women who read a page like this are not choosing between three diagnoses. They have one symptom, a long search history, and no clear idea which specialist to see. The practical answer is that one consultation and one examination will place the symptom, and the tests follow from that rather than the other way round.
Your first consultation at CION is free and runs to about 45 minutes. We do not order tests you do not need — a CA-125 in a 32-year-old with cyclical bloating and a normal examination answers nothing and worries everyone — and where the assessment is reassuring, we say so plainly instead of booking a follow-up scan to be seen to do something.
Where a cancer is confirmed, CION’s own team covers medical oncology and radiation oncology: chemotherapy, chemoradiation, maintenance therapy, and genetic counselling with BRCA and HRD testing, delivered across 35+ centres in Telangana and Andhra Pradesh. Gynaecologic-oncology surgery — debulking for ovarian cancer, hysterectomy with staging for endometrial cancer, radical surgery for early cervical cancer — is coordinated with specialist partner centres and may be billed there. We would rather say that upfront than have you discover it at the billing counter.
Free, unhurried and with a specialist. Long enough to take the history that decides which organ is in question and which tests you actually need.
Cases that raise a question are reviewed by medical oncology, radiation oncology, imaging and pathology together, rather than decided by a single clinician.
BRCA, HRD and Lynch-related testing, with counselling before and after, for women whose family history or diagnosis warrants it — and for their relatives.
Chemotherapy and follow-up can be given near where you live, across Telangana and Andhra Pradesh, instead of repeat trips to one city hospital.
The question underneath most searches like this is which of the three is the most dangerous. Published survival figures look as though they answer it. Mostly they do not. Cervical and endometrial cancer are frequently caught early — one by screening, the other by bleeding — while ovarian cancer is usually found after it has spread. A large part of the gap between their survival figures is a difference in when they are found, not in how aggressive they are.
The figures mislead in other ways too. They are historical, published years after the patients they describe were treated. They average across substages and tumour subtypes, and for ovarian cancer they mix women who had complete surgery with women who did not. None of that is visible in a single percentage.
CION publishes its own one-year survival alongside the national figure, so the comparison is visible rather than implied. For ovarian cancer, 81.0% of CION patients are alive at one year, against a national figure of 73.7%. These are one-year figures across the whole treated population — not cure rates, and not a prediction for any individual. Your own outlook depends on which cancer it is, its stage and subtype, and your general health, and it is a conversation to have with your oncologist rather than with a table.
CION ovarian cancer patients alive at one year from diagnosis. *One-year survival, CION treated population.
The comparable national figure for ovarian cancer. *One-year survival; national registry data.
Not a cure rate, and not a statement about you. Stage at diagnosis, subtype and general health matter far more to an individual outlook than any published average.
*One-year survival rates. CION figures reflect CION’s treated patient population; national figures are drawn from published Indian cancer registry data. Survival statistics describe groups, not individuals — discuss your own prognosis with your treating oncologist.
They start in three different places and behave accordingly. Cervical cancer begins in the neck of the womb and is caused, in virtually every case, by a persistent high-risk HPV infection. Endometrial cancer begins in the lining of the womb and is driven largely by long-term oestrogen exposure unopposed by progesterone, with obesity the biggest modifiable factor. Ovarian cancer begins in the ovary or fallopian tube and has no single cause, although inherited BRCA and Lynch variants account for a meaningful minority. The practical consequences follow from that: cervical cancer can be vaccinated against and screened for, endometrial cancer usually announces itself early with bleeding after the menopause, and ovarian cancer has neither a screening test nor a reliable early symptom, which is why it is most often found once it has already spread.
No, and the two are often confused because both organs sit in the pelvis. Uterine cancer means cancer of the womb, and in about nine out of ten cases it is endometrial cancer, arising in the lining. Ovarian cancer arises in the ovary or the fallopian tube. They differ in cause, in symptoms and in how they are usually found. Uterine cancer typically causes bleeding after the menopause and is usually caught at an early stage, when surgery alone is often enough. Ovarian cancer causes bloating, early fullness, pelvic pain and urinary urgency, and is usually found later, when surgery and chemotherapy are both needed. A less common group of uterine cancers, the sarcomas, arise in the muscle wall rather than the lining and behave differently again.
No, and this is the most consequential misunderstanding on this page. A Pap smear, and the HPV test that has largely replaced it, samples cells from the surface of the cervix. It is designed to find pre-cancerous change in the cervix, and it does that extremely well. It does not sample the ovaries, which sit several centimetres away and cannot be reached from the vagina, and it is not a reliable way of sampling the womb lining. A normal cervical screening result tells you about your cervix and nothing about your ovaries or your endometrium. Women have delayed getting bloating or postmenopausal bleeding checked because their smear was normal. If you have a symptom, it needs its own test, whenever you were last screened.
No. The HPV vaccine works by preventing infection with the high-risk virus types that cause almost all cervical cancer, and it also prevents a proportion of anal, vulval, vaginal and throat cancers driven by the same virus. Neither ovarian nor endometrial cancer is caused by HPV, so the vaccine has no effect on either. That is not an argument against vaccination: cervical cancer remains one of the commonest cancers in Indian women, and it is largely preventable through vaccination and screening together. It is simply a reminder that preventing one gynaecological cancer does not prevent the others. Lowering endometrial cancer risk is about weight, blood sugar and hormonal balance; lowering ovarian cancer risk in a woman with a strong family history is about genetic testing and, for confirmed high-risk carriers, risk-reducing surgery.
Endometrial cancer is usually caught earliest, because it causes bleeding after the menopause while it is still confined to the womb, and that symptom brings most women to a doctor within weeks. Cervical cancer varies enormously: where screening is used it is often prevented altogether or found as pre-cancer, while unscreened women commonly present late. Ovarian cancer is usually found latest. It has no screening test, the ovaries sit deep in the pelvis with room for a tumour to grow, and the symptoms it eventually produces are the same ones indigestion and irritable bowel syndrome produce every day. That is a statement about the disease, not about you. Ovarian cancer found early is treated very differently from ovarian cancer found late, which is the whole argument for acting on a persistent new pattern.
Sometimes, and it depends which one. BRCA1 and BRCA2 variants raise ovarian and breast cancer risk substantially and do not raise cervical or endometrial risk. Lynch syndrome raises the risk of bowel, endometrial and ovarian cancer together, and in women it is often endometrial cancer that appears first. So a family history of ovarian, breast, bowel or endometrial cancer, particularly at a young age or in more than one relative, is worth taking to a genetic counsellor rather than to a scanner. Cervical cancer is the exception: its cause is an infection rather than an inherited gene, so it does not cluster in families for genetic reasons. CION provides genetic counselling and BRCA and HRD testing in-house, including cascade testing for relatives once a variant has been found.
The first consultation is free and runs to about 45 minutes. CION treats all three. Medical oncology and radiation oncology are delivered by CION’s own team — chemotherapy, chemoradiation for locally advanced cervical cancer, maintenance therapy for ovarian cancer, and genetic counselling with BRCA and HRD testing — across more than 35 centres in Telangana and Andhra Pradesh. Gynaecologic-oncology surgery, including debulking for ovarian cancer and hysterectomy with staging for endometrial cancer, is coordinated with specialist partner centres and may be billed there; we say so upfront rather than leaving it to be discovered later. Every case is discussed at a tumour board before treatment starts, and eligible treatment may be covered under Aarogyasri or PMJAY at empanelled centres.